Follow
Karin de Visser
Karin de Visser
Verified email at nki.nl - Homepage
Title
Cited by
Cited by
Year
Paradoxical roles of the immune system during cancer development
KE De Visser, A Eichten, LM Coussens
Nature reviews cancer 6 (1), 24-37, 2006
26902006
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
SB Coffelt, K Kersten, CW Doornebal, J Weiden, K Vrijland, CS Hau, ...
Nature 522 (7556), 345-348, 2015
13262015
Neutrophils in cancer: neutral no more
SB Coffelt, MD Wellenstein, KE de Visser
Nature Reviews Cancer 16 (7), 431-446, 2016
12272016
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
CH Ries, MA Cannarile, S Hoves, J Benz, K Wartha, V Runza, ...
Cancer cell 25 (6), 846-859, 2014
11292014
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent
KE De Visser, LV Korets, LM Coussens
Cancer cell 7 (5), 411-423, 2005
8952005
FcRγ activation regulates inflammation-associated squamous carcinogenesis
P Andreu, M Johansson, NI Affara, F Pucci, T Tan, S Junankar, L Korets, ...
Cancer cell 17 (2), 121-134, 2010
5802010
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ...
Nature medicine 25 (6), 920-928, 2019
5132019
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
HL Greenstone, JD Nieland, KE De Visser, MLH De Bruijn, R Kirnbauer, ...
Proceedings of the National Academy of Sciences 95 (4), 1800-1805, 1998
4451998
Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape
MD Wellenstein, KE de Visser
Immunity 48 (3), 399-416, 2018
4122018
Genetically engineered mouse models in oncology research and cancer medicine
K Kersten, KE de Visser, MH van Miltenburg, J Jonkers
EMBO molecular medicine 9 (2), 137-153, 2017
3572017
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
S Rottenberg, AOH Nygren, M Pajic, FWB van Leeuwen, ...
Proceedings of the National Academy of Sciences 104 (29), 12117-12122, 2007
3512007
The inflammatory tumor microenvironment and its impact on cancer development
KE de Visser, LM Coussens
Infection and Inflammation: Impacts on Oncogenesis 13, 118-137, 2006
2742006
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
MD Wellenstein, SB Coffelt, DEM Duits, MH van Miltenburg, M Slagter, ...
Nature 572 (7770), 538-542, 2019
2682019
Effects of TGF-β on the immune system: implications for cancer immunotherapy
KE De Visser, WM Kast
Leukemia 13 (8), 1188-1199, 1999
2261999
Inflammation, proteases and cancer
LCL van Kempen, KE de Visser, LM Coussens
European journal of cancer 42 (6), 728-734, 2006
2232006
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
H Garner, KE de Visser
Nature Reviews Immunology 20 (8), 483-497, 2020
2032020
Developmental stage‐specific contribution of LGR5+ cells to basal and luminal epithelial lineages in the postnatal mammary gland
KE de Visser, M Ciampricotti, EM Michalak, DWM Tan, EN Speksnijder, ...
The Journal of pathology 228 (3), 300-309, 2012
1752012
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
F Reyal, MH Van Vliet, NJ Armstrong, HM Horlings, KE de Visser, M Kok, ...
Breast Cancer Research 10, 1-15, 2008
1602008
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
SB Coffelt, KE de Visser
Trends in immunology 36 (4), 198-216, 2015
1332015
The interplay between innate and adaptive immunity regulates cancer development
KE De Visser, LM Coussens
Cancer Immunology, Immunotherapy 54, 1143-1152, 2005
1232005
The system can't perform the operation now. Try again later.
Articles 1–20